(Q35044909)

6 August 2017

title

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection (English)

1 reference

6 August 2017

1 reference

12

Kazuhiko Koike

1 reference

6 August 2017

6

Kazuaki Chayama

1 reference

6 August 2017

7

Yoshiiku Kawakami

1 reference

6 August 2017

1

Hiromitsu Kumada

1 reference

6 August 2017

3

Kenji Ikeda

1 reference

6 August 2017

2

Yoshiyuki Suzuki

1 reference

6 August 2017

11

Namiki Izumi

1 reference

6 August 2017

13

Tetsuo Takehara

1 reference

6 August 2017

Joji Toyota

4

1 reference

6 August 2017

Yoshiyasu Karino

5

1 reference

6 August 2017

Akio Ido

8

1 reference

6 August 2017

Kazuhide Yamamoto

9

1 reference

6 August 2017

Koichi Takaguchi

10

1 reference

6 August 2017

Norifumi Kawada

14

1 reference

6 August 2017

Michio Sata

15

1 reference

6 August 2017

Hidetaka Miyagoshi

16

1 reference

6 August 2017

Timothy Eley

17

1 reference

6 August 2017

Fiona McPhee

18

1 reference

6 August 2017

Andrew Damokosh

19

1 reference

6 August 2017

Hiroki Ishikawa

20

1 reference

6 August 2017

Eric Hughes

21

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

6 August 2017

1 reference

6 August 2017

volume

59

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

2083-2091

1 reference

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Faldaprevir and deleobuvir for HCV genotype 1 infection.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Preliminary study of two antiviral agents for hepatitis C genotype 1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Telaprevir for retreatment of HCV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Telaprevir for previously untreated chronic hepatitis C virus infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Boceprevir for previously treated chronic HCV genotype 1 infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Boceprevir for untreated chronic HCV genotype 1 infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4315868

25 October 2018

Identifiers

DOI

10.1002/HEP.27113

1 reference

release_l73tgi2d2rffna5ttp43m7i4i4

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l73tgi2d2rffna5ttp43m7i4i4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

4315868

1 reference

6 August 2017

1 reference